NCT00393809
- Conditions
- Bladder Neoplasms, Carcinoma, Carcinoma, Transitional Cell, +13 more
- Locations
-
- E. Wolfson Medical Center Holon, Israel
- Meir Medical Center Kfar Saba, Israel
Clinical trial condition
Urinary Bladder Neoplasms
Explore clinical trials studying Urinary Bladder Neoplasms. Study availability and eligibility vary by location and protocol.
1,200 public trials
264 recruiting studies
Urinary Bladder Neoplasms trial results
NCT00491114
- Conditions
- Bladder Neoplasms, Female Urogenital Diseases, Female Urogenital Diseases and Pregnancy Complications, +9 more
- Locations
-
- For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician. Bologna, Italy
- For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician. Como, Italy
- For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician. Genova, Italy
- For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician. Padova, Italy
NCT00490880
- Conditions
- Bladder Cancer, Female Urogenital Diseases, Female Urogenital Diseases and Pregnancy Complications, +9 more
- Locations
-
- For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician. Warsaw, Poland
NCT00035061
- Conditions
- Disease Attributes, Female Urogenital Diseases, Female Urogenital Diseases and Pregnancy Complications, +15 more
- Locations
-
- Los Angeles, California, United States
- Palo Alto, California, United States
- Boca Raton, Florida, United States
- Tampa, Florida, United States
NCT00034593
- Conditions
- Female Urogenital Diseases, Female Urogenital Diseases and Pregnancy Complications, Male Urogenital Diseases, +12 more
- Locations
-
- "For additional information regarding investigative sites for this trial, contact the Clinical Trials Support Center at 1-877-CTLILLY (1-877-285-4559) or speak with your personal physician." Helsinki, Finland
- "For additional information regarding investigative sites for this trial, contact the Clinical Trials Support Center at 1-877-CTLILLY (1-877-285-4559) or speak with your personal physician." Pikonlinna, Finland
- "For additional information regarding investigative sites for this trial, contact the Clinical Trials Support Center at 1-877-CTLILLY (1-877-285-4559) or speak with your personal physician." Turku, Finland
- "For additional information regarding investigative sites for this trial, contact the Clinical Trials Support Center at 1-877-CTLILLY (1-877-285-4559) or speak with your personal physician." Bordeaux, France
Completed
Intravesical Epirubicin Plus BCG to Prevent the Recurrence of Transitional Cell Carcinoma of Bladder
NCT00343356
- Conditions
- Bladder Neoplasms, Carcinoma, Female Urogenital Diseases, +12 more
- Locations
-
Not specified
NCT00011518
- Conditions
- Bladder Cancer, Female Urogenital Diseases, Female Urogenital Diseases and Pregnancy Complications, +9 more
- Locations
-
- Allan Smith Research Office Berkeley, California, United States
Active, Not Recruiting
A Study of TAR-200 in Combination With Cetrelimab Versus Concurrent Chemoradiotherapy in Participants With Muscle-invasive Bladder Cancer (MIBC) of the Bladder
NCT04658862
- Conditions
- Female Urogenital Diseases, Female Urogenital Diseases and Pregnancy Complications, Male Urogenital Diseases, +8 more
- Locations
-
- Loma Linda Univ Faculty Medic Loma Linda, California, United States
- University of Southern California Los Angeles, California, United States
- Providence Saint John s Health Center Santa Monica, California, United States
- Stanford University Medical Center Stanford, California, United States
Active, Not Recruiting
Testing the Addition of Tazemetostat to the Immunotherapy Drug, Pembrolizumab (MK-3475), in Advanced Urothelial Carcinoma
NCT03854474
- Conditions
- Carcinoma, Carcinoma, Transitional Cell, Female Urogenital Diseases, +16 more
- Locations
-
- Mayo Clinic Hospital in Arizona Phoenix, Arizona, United States
- Mayo Clinic in Arizona Scottsdale, Arizona, United States
- Smilow Cancer Hospital-Derby Care Center Derby, Connecticut, United States
- Smilow Cancer Hospital Care Center-Fairfield Fairfield, Connecticut, United States
Active, Not Recruiting
Testing Combination Erdafitinib and Enfortumab Vedotin in Metastatic Bladder Cancer After Treatment With Chemotherapy and Immunotherapy
NCT04963153
- Conditions
- Carcinoma, Carcinoma, Transitional Cell, Female Urogenital Diseases, +36 more
- Locations
-
- Los Angeles General Medical Center Los Angeles, California, United States
- USC / Norris Comprehensive Cancer Center Los Angeles, California, United States
- UCHealth University of Colorado Hospital Aurora, Colorado, United States
- Moffitt Cancer Center Tampa, Florida, United States